64 related articles for article (PubMed ID: 34650804)
1. Combination of high anti-SKI and low anti-TMED5 antibody levels is preferable prognostic factor in esophageal carcinoma.
Ito M; Yajima S; Suzuki T; Oshima Y; Nanami T; Sumazaki M; Shiratori F; Takizawa H; Li SY; Zhang BS; Yoshida Y; Matsutani T; Hiwasa T; Shimada H
Cancer Sci; 2024 Apr; ():. PubMed ID: 38634426
[TBL] [Abstract][Full Text] [Related]
2. Serum anti-PCK1 antibody levels are a prognostic factor for patients with diabetes mellitus.
Namiki T; Takemoto M; Hayashi A; Yamagata H; Ishikawa T; Yokote K; Li SY; Kubota M; Zhang BS; Yoshida Y; Matsutani T; Mine S; Machida T; Kobayashi Y; Terada J; Naito A; Tatsumi K; Takizawa H; Nakamura R; Kuroda H; Iwadate Y; Hiwasa T
BMC Endocr Disord; 2023 Oct; 23(1):239. PubMed ID: 37904164
[TBL] [Abstract][Full Text] [Related]
3. Elevated levels of autoantibodies against DNAJC2 in sera of patients with atherosclerotic diseases.
Yoshida Y; Zhang XM; Wang H; Machida T; Mine S; Kobayashi E; Adachi A; Matsutani T; Kamitsukasa I; Wada T; Aotsuka A; Iwase K; Tomiyoshi G; Nakamura R; Shinmen N; Kuroda H; Takizawa H; Kashiwado K; Shin H; Akaogi Y; Shimada J; Nishi E; Ohno M; Takemoto M; Yokote K; Kitamura K; Iwadate Y; Hiwasa T
Heliyon; 2020 Aug; 6(8):e04661. PubMed ID: 32904265
[TBL] [Abstract][Full Text] [Related]
4. JMJD6 Autoantibodies as a Potential Biomarker for Inflammation-Related Diseases.
Zhang BS; Zhang XM; Ito M; Yajima S; Yoshida K; Ohno M; Nishi E; Wang H; Li SY; Kubota M; Yoshida Y; Matsutani T; Mine S; Machida T; Takemoto M; Yamagata H; Hayashi A; Yokote K; Kobayashi Y; Takizawa H; Kuroda H; Shimada H; Iwadate Y; Hiwasa T
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732153
[TBL] [Abstract][Full Text] [Related]
5. Cellular Impacts of Striatins and the STRIPAK Complex and Their Roles in the Development and Metastasis in Clinical Cancers (Review).
Li AX; Martin TA; Lane J; Jiang WG
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201504
[TBL] [Abstract][Full Text] [Related]
6. Striatins and STRIPAK complex partners in clinical outcomes of patients with breast cancer and responses to drug treatment.
Li AX; Zeng JJ; Martin TA; Ye L; Ruge F; Sanders AJ; Khan E; Dou QP; Davies E; Jiang WG
Chin J Cancer Res; 2023 Aug; 35(4):365-385. PubMed ID: 37691891
[TBL] [Abstract][Full Text] [Related]
7. Utility of atherosclerosis-associated serum antibodies against colony-stimulating factor 2 in predicting the onset of acute ischemic stroke and prognosis of colorectal cancer.
Li SY; Yoshida Y; Kubota M; Zhang BS; Matsutani T; Ito M; Yajima S; Yoshida K; Mine S; Machida T; Hayashi A; Takemoto M; Yokote K; Ohno M; Nishi E; Kitamura K; Kamitsukasa I; Takizawa H; Sata M; Yamagishi K; Iso H; Sawada N; Tsugane S; Iwase K; Shimada H; Iwadate Y; Hiwasa T
Front Cardiovasc Med; 2023; 10():1042272. PubMed ID: 36844744
[TBL] [Abstract][Full Text] [Related]
8. Serum Anti-BRAT1 is a Common Molecular Biomarker for Gastrointestinal Cancers and Atherosclerosis.
Hu L; Liu J; Shimada H; Ito M; Sugimoto K; Hiwasa T; Zhou Q; Li J; Shen S; Wang H
Front Oncol; 2022; 12():870086. PubMed ID: 35656505
[TBL] [Abstract][Full Text] [Related]
9. The combination of positive anti‑WDR1 antibodies with negative anti‑CFL1 antibodies in serum is a poor prognostic factor for patients with esophageal carcinoma.
Ito M; Yajima S; Suzuki T; Oshima Y; Nanami T; Sumazaki M; Shiratori F; Wang H; Hu L; Takizawa H; Li SY; Iwadate Y; Hiwasa T; Shimada H
Med Int (Lond); 2023; 3(2):11. PubMed ID: 36875818
[TBL] [Abstract][Full Text] [Related]
10. Serum anti-LRPAP1 is a common biomarker for digestive organ cancers and atherosclerotic diseases.
Sumazaki M; Shimada H; Ito M; Shiratori F; Kobayashi E; Yoshida Y; Adachi A; Matsutani T; Iwadate Y; Mine S; Machida T; Kamitsukasa I; Mori M; Sugimoto K; Uzawa A; Kuwabara S; Kobayashi Y; Ohno M; Nishi E; Maezawa Y; Takemoto M; Yokote K; Takizawa H; Kashiwado K; Shin H; Kishimoto T; Matsushita K; Kobayashi S; Nakamura R; Shinmen N; Kuroda H; Zhang XM; Wang H; Goto KI; Hiwasa T
Cancer Sci; 2020 Dec; 111(12):4453-4464. PubMed ID: 32939876
[TBL] [Abstract][Full Text] [Related]
11. Elevation of Autoantibody in Patients with Ischemic Stroke.
Yoshida Y; Hiwasa T; Machida T; Kobayashi E; Mine S; Matsushima J; Takiguchi M; Iwadate Y
Neurol Med Chir (Tokyo); 2018 Jul; 58(7):303-310. PubMed ID: 29848906
[TBL] [Abstract][Full Text] [Related]
12. Identification of serum anti-striatin 4 antibodies as a common marker for esophageal cancer and other solid cancers.
Ito M; Hiwasa T; Oshima Y; Yajima S; Suzuki T; Nanami T; Sumazaki M; Shiratori F; Funahashi K; Takizawa H; Kashiwado K; Tochigi N; Shimada H
Mol Clin Oncol; 2021 Nov; 15(5):237. PubMed ID: 34650804
[TBL] [Abstract][Full Text] [Related]
13. Association of Serum Anti-PCSK9 Antibody Levels with Favorable Postoperative Prognosis in Esophageal Cancer.
Ito M; Hiwasa T; Oshima Y; Yajima S; Suzuki T; Nanami T; Sumazaki M; Shiratori F; Funahashi K; Li SY; Iwadate Y; Yamagata H; Jambaljav B; Takemoto M; Yokote K; Takizawa H; Shimada H
Front Oncol; 2021; 11():708039. PubMed ID: 34504788
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
